
|Articles|May 1, 2004
Some Insurers Still Reluctant to Pay for New Biologic Drugs
Maui, Hawaii - Some insurers are reluctant to pay for the new biologic drugs for psoriasis, despite the approval of two of the drugs by the U.S. Food and Drug Administration, according to William Abramovits, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Advancing Topical Stewardship and Expanding Nonsteroidal Options
2
Hilary Baldwin, MD, Highlights Emerging Acne and Rosacea Therapies at Elevate-Derm
3
Douglas DiRuggiero, PA-C, DMSc, Recognized at the Elevate-Derm Fall Conference
4
Education and Engagement Drive Momentum in Hair Disorders
5



















